GE BioPharma sale to Danaher is complete

By The Science Advisory Board staff writers

April 1, 2020 -- The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

As part of Danaher, the business will be called Cytiva and will operate as a standalone company within Danaher's Life Sciences segment.

The deal, which was originally announced in February 2019, was completed with a cash consideration of around $20 billion to GE as well as Danaher's assumption of certain pension liabilities.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.